Cargando…

Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents

BACKGROUND: A series of coumarin-indole hybrids was synthesized as the new α-glucosidase inhibitors. The title hybrids were considered as α-glucosidase inhibitors because had two active pharmacophores against α-glucosidase: coumarin and indole. METHODS: The thirteen various derivatives 4a–m were syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Niri, Davood Rezapour, Sayahi, Mohammad Hosein, Behrouz, Somayeh, Moazzam, Ali, Mojtabavi, Somayeh, Faramarzi, Mohammad Ali, Larijani, Bagher, Rastegar, Hossein, Mohammadi-Khanaposhtani, Maryam, Mahdavi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635080/
https://www.ncbi.nlm.nih.gov/pubmed/36329490
http://dx.doi.org/10.1186/s13065-022-00882-2
Descripción
Sumario:BACKGROUND: A series of coumarin-indole hybrids was synthesized as the new α-glucosidase inhibitors. The title hybrids were considered as α-glucosidase inhibitors because had two active pharmacophores against α-glucosidase: coumarin and indole. METHODS: The thirteen various derivatives 4a–m were synthesized, purified, and fully characterized. These compounds were evaluated against α-glucosidase in vitro and in silico. In silico pharmacokinetic studies of the most potent compounds were also performed. RESULTS: Most of the title compounds exhibited high anti-α-glucosidase activity in comparison to standard drug acarbose. In particular, the phenoxy derivative 4d namely 3-((1H-indol-3-yl)(3-phenoxyphenyl)methyl)-4-hydroxy-2H-chromen-2-one showed promising activity. This compound is a competitive inhibitor against α-glucosidase and showed the lowest binding energy at the α-glucosidase active site in comparison to other potent synthesized compounds and acarbose. CONCLUSION: Compound 4d can be a lead compound for further structural development to obtain effective and potent α-glucosidase inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-022-00882-2.